
give my patients peace of mind with fast and sensitive CML monitoring results
Blood Cancer
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia (CML) is one of the most common hematologic malignancies, accounting for 15% of all leukemias in adults.1 Primarily affecting adults who are older than 64 years of age, CML is rarely seen in children.2 Current therapies for CML make this a highly treatable disease with a survival rate of greater than 90% on effective tyrosine kinase inhibitor therapy.3
CML Treatment
CML Treatment
>90% of CML patients survive more than 5 years after their initial diagnosis22
In the last 15 years we have seen extraordinary breakthroughs in the management of Chronic Myeloid Leukemia (CML) with the introduction of tyrosine kinase inhibitors (TKIs). TKIs are a class of drugs that block the function of the abnormal tyrosine kinase protein, stopping the excessive build-up of immature blood cells.
The efficacy of TKI therapy is often assessed with hematologic and molecular testing which is measured alongside time-bound milestones, helping to inform treatment decisions.7
Molecular testing is performed using real-time quantitative polymerase chain reaction (RT-qPCR) to determine molecular response throughout CML treatment. These results are standardized against the International Scale to minimize variability and to quantify the level of BCR-ABL1 transcripts present in CML patients.7
Fast CML Monitoring
Fast CML Monitoring
61% of CML patients who have agreed with their doctor to discontinue treatment suffer a molecular
relapse7
The recommended method for regular molecular monitoring of Chronic Myeloid Leukemia (CML) is real-time quantitative polymerase chain reaction (RT-qPCR). The monitoring test should report on the International Scale (%IS) and be repeated several times a year.8
An estimated 40%-60% of CML patients in the chronic phase can achieve a sustained deep molecular response (DMR) for greater than 2 years through TKI treatment making them eligible for treatment discontinuation. The cessation of medication is possible with an emphasis on strict and regular CML monitoring to ensure prompt action can be taken in cases of relapse. This is considered a functional cure even though evidence of CML may remain present but at a level that is safe and stable to manage without TKI treatment.7
Of the patients who relapse, 95% of these CML patients relapse within 7 months of treatment cessation. There is a greater need for fast and sensitive molecular diagnostic testing to support timely treatment decisions.7